| Thursday, May 16, 2024: Morning General Sessions |
| 7:00 - 8:00 a.m. |
Breakfast and Registration |
| 8:00 - 9:00 a.m. |
Keynote Address | Patient Blood Management: The Why, But Better Yet, Why Not?
Carolyn D. Burns, MD
President, SABM
CMO/Co-Founder, Collaborative Clinical Consulting, LLC.
Speaker Bio: Carolyn Burns, MD, is a Board-Certified Pathologist (AP/CP) and served as Medical Director/Chief of Pathology of the Jewish Hospital Healthcare System, Dept. of Pathology in Louisville, KY. from 1991-2011. This included medical directorship of Surgical Pathology, Clinical Laboratory, and the Transfusion/Tissue Services for this 5-hospital system. She has previously been an Asst. Clinical Professor in the Dept. of Pathology at the University of Louisville and on the Advisory Board and guest lecturer for the Bellarmine University Clinical Laboratory Science Program.
After earning her Microbiology undergraduate degree and her subsequent Medical Degree, Dr. Burns completed an internship in General Surgery followed by Pathology residency at the University of Louisville.
Dr. Burns is the current President for the Society for the Advancement of Patient Blood Management, having served as Secretary and Treasurer along with SABM Newsletter editor-in-chief. Dr. Burns is an active member of several medical societies including AABB, College of American Pathologists, and the American Society of Clinical Pathologists. She is a board member for the Kentucky Association of Blood Banks.
Dr. Burns is a Patient Blood Management physician advisor/consultant working with numerous hospitals and systems throughout the U.S. She is the CMO of Collaborative Clinical Consulting, LLC, a company providing PBM education, implementation services, perioperative assessment, and Lean Six Sigma services.
Abstract: This presentation will emphasize the pillars of PBM practice, the concept of Blood Health, and the role laboratory professionals play within this practice.
Objectives – the learner will be able to:
- Review the pillars of PBM and the concept of Blood Health.
- Highlight and differentiate PBM from optimal blood use (OBU).
- Emphasize the important roles of laboratory professionals within the healthcare team in PBM implementation.
|
| 9:00 - 9:45 a.m. |
Perioperative Anemia Optimization – A Multispecialty Collaboration
Marjorie Gloff, MD
Associate Professor of Anesthesiology & Perioperative Medicine
University of Rochester
Speaker Bio: Dr. Marjorie Gloff is a board-certified anesthesiologist. After attending the University of Rochester for medical school and subsequently her residency in anesthesiology, she joined the faculty in 2012. In the Department of Anesthesiology and Perioperative Medicine, she serves in the roles of Associate Chair of Perioperative Medicine and the Director of the Center for Perioperative Medicine, the perioperative optimization clinic for patients requiring anesthesia and surgical services at UR Medicine locations throughout Monroe County.
Her clinical practice and academic interests focus on perioperative optimization. She also has a passion for quality improvement and as such serves as the Associate Chief Medical Officer for Patient Safety and Loss Prevention at the University of Rochester. Dr. Gloff was named the 2020 UR Medicine Board Excellence Physician of the Year and the Society for Perioperative Assessment and Quality Improvement’s Physician of the Year in 2023.
She is the current Secretary for the Society for Perioperative Assessment and Quality Improvement (SPAQI). She is also an active member of the NYS Society of Anesthesiologists and sits on both the Committee for Women Physicians and the Committee for Patient Safety and Quality Improvement. She is also an active member of the American Society of Anesthesiologists and the Society of Ambulatory Anesthesia.
Abstract: This presentation will include a review of current best practices in perioperative anemia with a focus on how one center utilized a multispecialty collaboration to further the optimization of anemia in, at times, a narrow time frame.
Objectives – the learner will be able to:
- Understand the impact of perioperative anemia in the patient.
- Highlight the importance of a multispecialty system approach to this problem.
|
| 9:45 - 10:00 a.m. |
Break |
| 10:00 - 10:30 a.m. |
Blood Conservation Techniques in Pediatric Cardiopulmonary Bypass
Ron Angona, MS, MBA, CCP
Chief, Division of Pediatric Perfusion
University of Rochester Medical Center
Speaker Bio: Ron Angona is a 2001 graduate from the SUNY Perfusion program in Syracuse, NY. Ron has spent the majority of his career at the University of Rochester Medical Center, performing both adult and pediatric cardiopulmonary bypass. His primary focus has been on neonatal and infant bypass and bypass techniques surrounding blood conservation. In 2014 Ron received a Masters in Medical Management from the Simon School of Business at the University of Rochester, and in 2021 Ron received his MBA, also from U of R.
Ron has been a longstanding member of AmSECT, the American Society of Extracorporeal Technology, through which he has held numerous positions, including being the former Chair of the Pediatric and Congenital Perfusion Committee. Ron has been involved in the planning of numerous national conferences and has presented dozens of times on a variety of perfusion topics, both adult and pediatric.
Currently, Ron is the Chief of the Division of Pediatric Perfusion at the University of Rochester Medical Center, Golisano Children’s Hospital, where he oversees both the pediatric perfusion department as well as the pediatric ECMO team.
Abstract: The focus of this presentation will be on controllable aspects of blood conservation from the Perfusionist’s perspective with a description of bypass circuit miniaturization techniques. A variety of techniques will be briefly described.
Objectives – the learner will be able to:
- Identify different blood conservation techniques that are utilized in pediatric cardiopulmonary bypass.
- Understand the current limitations of blood conservation techniques in pediatric bypass, with a discussion on products and equipment currently available.
|
| 10:30 - 11:00 a.m. |
Bloodless Medicine and Surgery: Can It Contribute to Health Equity?
Sharon V. Sledge, MA, MS, RN
Patient Blood Management Coordinator
NYU Langone Health
Speaker Bio: Sharon Sledge, MA, MS, RN, is the Patient Blood Management Coordinator at NYU Langone Medical Center in New York, NY. Sharon has played a central role in preparing a bloodless medicine and surgery program for transition to a system-wide patient blood management program. She has been a nurse for 40 years with experience in critical care, perinatal, OR, home health, and various administrative positions. During the past 18 years, her career has focused exclusively on Patient Blood Management where she has revitalized, developed, and expanded four patient blood management/bloodless medicine programs that have achieved recognition both domestically and internationally for their cutting-edge advances in this field. Sharon has lectured at several national and international conferences on anemia and patient blood management. She recently completed her second term on the Board of Directors for the Society for the Advancement of Patient Blood Management.
Abstract: This presentation will contain an overview of Bloodless Medicine and Surgery including history, Bloodless Medicine and Surgery Programs, Pillars of Bloodless Medicine, Patient Advocacy for the Bloodless Patient (including minors), and implications for addressing healthcare disparities among patients seeking transfusion-free healthcare.
Objectives – the learner will be able to:
- Identify the 4 pillars of Bloodless Medicine and Surgery.
- Defend the role of Bloodless Medicine and Surgery in addressing healthcare disparities.
- Examine the partnership between Bloodless Medicine and the Blood Bank.
|
| 11:00 - 11:45 a.m. |
Bloodletters and Leechers: Therapeutic Apheresis
Nicole Aqui, MD
Section Chief, Apheresis and Transfusion Services
Hospital of the University of Pennsylvania
Speaker Bio: Dr. Nicole Aqui is an Associate Professor of Pathology and Laboratory Medicine at the University of Pennsylvania where she serves many important roles, including Vice Chair for Inclusion, Diversity and Equity, Pathology Residency Program Director, and Section Chief for Transfusion and Apheresis Services. Dr. Aqui is nationally recognized expert in apheresis, having co-authored evidence-based guidelines for the use of therapeutic apheresis in clinical practice. She is an active member of several professional societies, including serving as the President-Elect for the American Society for Apheresis. Dr. Aqui's clinical practice emphasis is on improving care of sickle cell patients transitioning to adult care. She has been inducted into the Academy of Master Clinicians, the highest clinical honor for a Penn Medicine physician in recognition of her leadership in exceptional patient care. In 2022 and 2023, Penn's Apheresis Clinic was awarded the national Press Ganey Pinnacle of Excellence Award for Human Experience Award for Outpatient Practices.
Abstract: Apheresis is a general term that refers to the removal of whole blood from a donor or patient, separation into individual components with the removal of a specific component and the return of the remaining components. This session will utilize case studies to review common conditions treated with apheresis. The presentation and pathophysiology of the disease entities, as well as the specific procedure used for treatment will be discussed. This presentation will focus on therapeutic plasma exchange, red cell exchange, and leukapheresis. Particular emphasis will be placed on how to approach requests for apheresis and the use of the 2023 American Society for Apheresis Guidelines, including the ASFA categories and recommendation grades.
Objectives – the learner will be able to:
- Utilize case studies to examine common conditions treated with apheresis.
- Highlight the American Society for Apheresis guidelines on the use of therapeutic apheresis.
- Review adverse effects of apheresis procedures.
|
| 11:45 a.m. - 12:45 p.m. |
Lunch / Business Meeting / Vendor Exhibit Hall |
| 12:45 - 1:15 p.m. |
Vendor Exhibit Hall with Dessert Bar |
Back to top
| Thursday, May 16, 2024: Afternoon Breakout Sessions |
| |
Track 1: Scientific |
Track 2: Immunohematology |
| 1:15 - 2:45 p.m. |
Reticulocytes in Donor Units Are an Underappreciated Risk Factor for RBC Alloimmunization
Krystalyn Hudson, PhD
Assistant Professor
Columbia University
Speaker Bio: Dr. Krystalyn Hudson is an Assistant Professor and co-Director of the Laboratory of Transfusion Biology at Columbia University. Dr. Hudson received her PhD in Immunology from Emory University and has developed an extramurally-funded line of research focusing on unraveling the intricacies of immune responses to red blood cells (RBCs), including autoimmunity and alloimmunity. Most recently, Dr. Hudson’s team made a seminal observation that patients with sickle cell disease abnormally retain functional mitochondrial in their mature RBCs, which may play a role in alloantibody production; based on this finding, they recently found that mitochondria-containing reticulocytes enhances RBC alloimmunization.
Abstract: RBC transfusion is the most common therapeutic procedure provided to hospitalized patients, with ~11 million transfusions per year in the USA. Although transfusions can be lifesaving, some patients develop clinically significant alloantibodies against donor RBC blood group antigens; these alloantibodies have adverse effects, including fatalities, in transfusion, pregnancy, and transplant settings. Because there are few strategies (with limited efficacy) to prevent or treat RBC alloimmunization, there is a clinical need to identify additional risk factors to minimize potential alloimmunization. This presentation will discuss our new finding that reticulocytes in donor RBC units enhance alloimmunization and detail the mechanistic underpinnings of reticulocyte-mediated RBC alloantibody production.
Objectives – the learner will be able to:
- Describe the differences between reticulocytes and mature RBCs.
- Examine how reticulocytes promote RBC alloantibody production.
Engineered T Cell Immunotherapies for Immune Modulation Beyond Oncology
Vijay Bhoj, MD, PhD
Assistant Professor
University of Pennsylvania
Speaker Bio: Dr. Bhoj earned his M.D. and Ph.D. at the University of Texas Southwestern Medical Center in Dallas where he studied innate antiviral immunity. He moved to the University of Pennsylvania where he completed residency in clinical pathology followed by a fellowship in transfusion medicine. He conducted post-doctoral training with Michael Milone when he became interested in leveraging an emerging technology, namely CAR T cells, for treatment of conditions beyond oncology. Dr. Bhoj joined the faculty at Penn, where his independent lab continues to develop cell therapies aimed at immune modulation, primarily in the contexts of autoimmunity and transplantation. He has extensive experience in the development of novel CAR T cell therapies and has led development of two CAR T platforms which are currently being evaluated in clinical trials.
Abstract: This presentation will discuss updates in the field of engineered T cells such as CAR T cells, in particular as they relate to treatment of non-cancer conditions such as organ transplantation and autoimmune diseases.
Objectives – the learner will be able to:
- Summarize the current landscape of CAR T cell development in non-oncology sphere.
- Provide examples of application of engineered T cells to mitigate rejection in organ transplantation.
A Novel Mouse Model for Platelet Transfusion
Elizabeth F. Stone, MD, PhD
Assistant Professor, Department of Pathology & Cell Biology
Columbia University Irving Medical Center
Assistant Attending, Transfusion Medicine and Cellular Therapy
NewYork-Presbyterian Columbia
Medical Director of Clinical Pathology and Laboratory Medicine
NewYork-Presbyterian Westchester Hospital
Speaker Bio: Dr. Elizabeth Stone is an Assistant Professor of Pathology & Cell Biology at Columbia University Irving Medical Center, where she practices Transfusion Medicine at Columbia University Irving Medical Center as an Assistant Attending and is the Medical Director of Clinical Pathology at NewYork-Presbyterian Westchester. As a Principal Investigator in the Laboratory of Transfusion Biology, Dr. Stone has pioneered a mouse model for platelet transfusion with interest in optimizing platelet transfusion storage and outcomes. Dr. Stone is also an active clinical educator across Divisions and Departments at Columbia University to promote best transfusion practices across the NewYork-Presbyterian enterprise, and she was awarded the Joseph Fink Teaching Award for her resident teaching in Pathology. She currently serves as the Secretary for BBANYS and is the co-chair of the BBANYS Education Committee.
Abstract: Platelets are required for hemostasis. Platelet transfusions are continuing to increase with medical advances. Although platelet units are evaluated by in vitro methods and post-transfusion recovery, it remains unclear how modifications and storage duration change platelet function in vivo. Additionally, studying platelet function in vivo has significant challenges. Thus, we developed a model to study platelet transfusion in vivo. Herein, we present a platelet transfusion murine model meeting FDA criteria adapted to mice, with units demonstrating pH > 6.2, low white blood cell counts, 24-hour post-transfusion recovery > 60%, and with transfused platelets found in clots.
Objectives – the learner will be able to:
- Understand the history of platelet transfusions and how platelet units are assessed.
- Describe the utility of animal models to study platelet transfusions, including strengths and limitations.
|
Anti-e: Auto or Allo, Worrisome or Benign?
Lynsi Rahorst, MHPE, MLS(ASCP)SBBCM
Manager, Education & Training, IRL/Genomics Laboratories
New York Blood Center Enterprises
Speaker Bio: After working for several years in the Immunohematology Reference Laboratory at Community Blood Center in Kansas City, Lynsi now works as the Manager of Education and Training for IRL/Genomics for New York Blood Center Enterprises (NYBCe). In this role, she supports training of laboratory staff and coordinates educational programs and content offered by NYBCe for the greater transfusion medicine community. She has a Masters Degree in Health Professions Education and is certified as a Specialist in Blood Banking. She has served on multiple education-related committees for AABB and is active in the AABB Spanish language section. Lynsi is passionate about educating and training the next generation of leaders in immunohematology and genomics, as well as supporting blood banking educational initiatives in Spanish-speaking countries.
Abstract: With the complexity of the Rh blood group system, it can be challenging to differentiate allo- vs autoantibody with Rh specificity, particularly when detected in patients who receive chronic transfusions. This case will provide a discussion of both serologic and genomics tests available to help define an antibody, and how the interpretation of these tests, along with clinical evaluation of the patient, can contribute to the most appropriate transfusion recommendations.
Objectives – the learner will be able to:
- Discuss serologic testing that may be used to classify an Rh antibody as auto or alloantibody, particularly in patients who are chronically transfused.
- Describe how blood group genotyping can contribute to our understanding of an Rh antibody.
- List transfusion options in a patient with complex Rh antibodies.
Transfusion Management of a Patient with anti-U When U Negative RBCs Are Scarce
Hallie Lee-Stroka, MT(ASCP)SBB
Immunohematologist
New York Blood Center
Speaker Bio: Hallie has 30+ years of lmmunohematology Reference Laboratory experience at New York Blood Center, National Institutes of Health, and American Red Cross.
Abstract: The purpose of this presentation is to illustrate the importance of obtaining molecular information on both the patient and donor who serologically type as S and s antigen negative. We will discuss how this information is critical for patients with anti-U in RBC selection for transfusion; however, when there is a lack of available RBCs or when molecular results are pending it is critical to have a management plan in place.
Objectives – the learner will be able to:
- Distinguish between a true U negative antigen classification and a Uvar+, both serologically and by molecular methods.
- Understand the serologic testing that should be performed on patients with anti-U prior to requesting RBCs for transfusion.
Evaluation of Platelet Transfusion Refractoriness
Treyc Terry, MD
Transfusion Medicine Fellow
University of Rochester Medical Center (URMC)
Speaker Bio: Treyc Terry, MD, is a transfusion medicine fellow at the University of Rochester Medical Center in Rochester, New York. Originally from Alexandria, Louisiana, he received his undergraduate degree from Xavier University of Louisiana and medical degree from University of Rochester School of Medicine and Dentistry in 2020. Dr. Terry completed a clinical pathology residency at the University of Rochester in 2023. His current research focuses on whole blood usage and outcomes, patient blood management, and stem cell engraftment in transplant patients. In the future, he plans to become a medical director of a blood bank.
Abstract: Thrombocytopenia, or low platelet count, can be caused by increased platelet destruction, and decreased platelet production. Patients can have thrombocytopenia due to immune or nonimmune causes. Platelet transfusion is often used to stop active bleeds, or to prevent bleeding, by maintaining the platelet count above a certain threshold. Suboptimal response to platelet transfusion on repeated episodes may lead to clinicians to suspect platelet transfusion refractoriness.
Objectives – the learner will be able to:
- Define platelet transfusion refractoriness, and identify how to measure refractoriness by using the correct count increment (CCI) or percentage platelet recovery (PPR).
- Determine the immune, or nonimmune causes of platelet refractoriness, and understand how the Human Leukocyte Antigen (HLA) system is used in evaluation, management, and treatment of this diagnosis.
|
Back to top
| Thursday, May 16, 2024: Evening General Sessions |
| 2:45 - 3:00 p.m. |
Break |
| 3:00 - 3:30 p.m. |
Apheresis Decision-making When There is Little or Poor-quality Evidence: Pushing Back and Adding Value as a Medical Consultant
Patricia A. R. Brunker, MD, DPhil(Oxon)
Medical Director, Blood Transfusion Service, Patient Services Section
Massachusetts General Hospital
Speaker Bio: Dr. Brunker is an Assistant Professor at Harvard Medical School (HMS) and Medical Director for Patient Services for the Blood Transfusion Service at Massachusetts General Hospital, which includes oversight of the apheresis service. She went to Brown Medical School and did research training in biological anthropology (MSc) and human genetics (DPhil) from the University of Oxford. Her clinical training is in surgery and anatomic and clinical pathology at HMS, with an MHS from the Johns Hopkins School of Public Health. She is also the program director of the Harvard Joint Program in Transfusion Medicine Fellowship at Mass General Brigham and Children’s Hospital Boston.
Abstract: Using examples from the case files of the Massachusetts General Hospital, we will review prevalence of requests for therapeutic apheresis consultation that did and did not include a recommendation to perform the procedure that was initially requested. The transfusion medicine consultant has an important role in the multidisciplinary approach to therapeutic apheresis in the many scenarios for which there is limited, or no, strong evidence to guide practice.
Objectives – the learner will be able to:
- Describe the prevalence of declined procedure requests for therapeutic plasma exchange (TPE) and red blood cell exchange at a major academic medical center.
- Understand the pathophysiology of hypertriglyceridemic pancreatitis and the rationale to avoid TPE in this setting.
- Understand successful strategies to manage heparin-induced thrombocytopenia without TPE.
|
| 3:30 - 4:00 p.m. |
Growing Variations in Collections Requirements – Why, Where, What
Joseph (Yossi) Schwartz, MD, MPH
Director, Transfusion Medicine and Blood Bank
Moffitt Cancer Center
Speaker Bio: Dr. Schwartz received his MD from the Technion – Israel Institute of Technology and his MPH from Columbia University Mailman School of Public Health. He completed Internal Medicine residency & Hematology Fellowship in Israel and a Transfusion Medicine/Blood Banking Fellowship at New York Blood Center. Upon completion of training, he pursued a decades-long career in promoting excellence in the field of Transfusion Medicine, Apheresis & Cellular Therapy across a multitude of facilities. He had served as a Professor of Pathology & Cell Biology at Columbia University Irving Medical Center, and then a Professor of Pathology, Molecular, and Cell-based Medicine at the Icahn School of Medicine at Mount Sinai before moving to the Moffitt Cancer Center & Research Institute as a Senior Member Member in the Department of Pathology/ Hematopathology and Laboratory Medicine. In these capacities, he amounted many years of experience directing Transfusion Medicine, Apheresis & Cellular Therapy Services.
Throughout his tenure in the field, Dr. Schwartz became an active member of the professional and academic community, serving on standardization committees, executive boards, and conference planning steering groups. He had been involved in many professional organizations including AABB, CAP, ISCT, and WBMT to name a few. He served as a director and an officer of the American Society for Apheresis (ASFA), rising to be the president in 2018-2019. Seeking to impact clinical practice worldwide, he served on the writing committee of ASFA’s special issue (published on 3-year cycles) for the last five editions. Thus, he was part of the codification efforts of evidence-based best-in-class clinical Therapeutic Apheresis. Furthermore, he promoted quality and standardization through dissemination of the FACT-JACIE international standards for cellular therapy (Standards Committee Chair, Inspector, Workshop Speaker). For these efforts and many more, he has earned many honors including the AABB Hemphill Jordan Leadership Award (2019), ASFA’s Presidential Award (2021), and ASFA’s Francis Morrison Lectureship Award (2023).
Abstract: With the expansion of the cell & gene therapy space, increased variations in the requirements for cell collections are a cause for concern for the apheresis community. This presentation will discuss why there are variations in collections’ requirements and provide solutions trying to mitigate these variations.
Objectives – the learner will be able to:
- Describe where we are now with the growing field of Cell & Gene Therapy (CGT).
- Address why there are variations in collections requirements for CGT.
- Discuss what can be done in order to decrease this variability.
|
| 4:00 - 4:30 p.m. |
Transfusion Reactions/Marginal Case Studies
Ghazala Nathu, MS, MD, PhD, FABC
Medical/Clinical Pathology Laboratory Director
Bassett Medical Center (Assistant Director)
Cobleskill Regional Hospital (Director)
O'Connor Hospital (Director)
Molecular Director/Blood Bank, Tissue Compliance Office
Speaker Bio: Dr. Ghazala Nathu has been practicing Clinical/Medical Pathology medicine for the past 39 years at various hospitals, including Bassett Medical Center, Cobleskill Regional Hospital, and O' Connor Hospital.
Abstract: The presentation will cover an overview of Transfusion Reactions, upon the transfusion of Blood and/or blood products that can occur in patients. Eight case studies showing the different types of transfusion reactions, including symptoms that can occur in patients, will be reviewed. An overview of what happens when a possible transfusion reaction is called for investigation will be presented.
Objectives – the learner will be able to:
- Identify NYS DOH/Regulatory Agency guidelines of transfusion media.
- Discuss early identification of common transfusion reactions.
- Have knowledge of different type of transfusion reaction a patient can have, and physicians/nursing interventions for the patient with transfusion reactions.
|
| 4:30 - 6:00 p.m. |
Vendor Exhibit Hall / Poster Presentations / Awards / Happy Hour
Now accepting Poster Presentation abstracts! Submit your abstract by April 30, 2024.
|
Back to top
| Friday, May 17, 2024 |
| 7:00 - 8:00 a.m. |
Breakfast and Registration |
| 8:00 - 8:45 a.m. |
Look Before You Leap: Critically Reviewing Trauma Transfusion Literature
Richard L. Haspel, MD, PhD
Professor of Pathology
Beth Israel Deaconess Medical Center and Harvard Medical School
Speaker Bio: Dr. Haspel is the Vice Chair for Medical Education at Beth Israel Deaconess Medical Center and a Professor of Pathology at Harvard Medical School. He has published a resident evidence-based transfusion medicine curriculum and has also spoken nationally on topics related to trauma and transfusion.
Abstract: Using studies of pre-hospital transfusion as a model, this presentation will discuss approaches to critically evaluate the medical literature.
Objectives – the learner will be able to:
- Critically review papers to identify potential pitfalls in research study design and interpretation.
- Discuss the literature regarding pre-hospital transfusion.
|
| 8:45 - 9:15 a.m. |
Automated Red Cell Exchange for Patients with Sickle Cell Disease
Akua Asante, MD
Assistant Professor of Pathology and Laboratory Medicine
University of Rochester Medical Center
Speaker Bio: Dr. Asante is an Assistant Professor of Pathology and Laboratory Medicine at the University of Rochester. She graduated from the University of Rochester Pediatric Hematology and Oncology Fellowship Program in 2019 and is currently working the Blood Bank. Dr. Asante's clinical interests include the evaluation and management of children and adults with Sickle cell disease. She is currently in the early phases of developing an observational study focused on alloimmunization in the sickle cell patient population served by the URMC Blood Bank.
Abstract: Sickle cell disease is an inherited disorder of red blood cells characterized by hemolysis and inflammation. Automated red cell exchange is an important treatment used to manage severe complications of sickle cell disease. This session will briefly review the pathophysiology of sickle cell disease followed by a more in-depth overview of automated red cell exchange particularly focusing on the indications, risks, and benefit of the procedure.
Objectives – the learner will be able to:
- Briefly describe the pathophysiology of sickle cell disease.
- Outline transfusion options for patients with sickle cell disease.
- Review the indications, risks, and benefits of automated red cell exchange for patients with sickle cell disease.
|
| 9:15 - 9:50 a.m. |
Managing Anticoagulation in Patients Undergoing Therapeutic Apheresis
Erin Horstman, MD
Assistant Professor
Yale University
Speaker Bio: Dr. Horstman attended Medical School at the University at Buffalo where she also completed Pathology Residency (AP/CP). After that, she relocated to New Haven, CT to complete fellowship training in Blood Banking/Transfusion Medicine and Hematopathology at Yale. She is currently an Associate Professor in the Department of Laboratory Medicine at Yale University where her focus is on Blood Banking, Apheresis, and laboratory evaluation of hematologic disorders including benign and malignant diseases.
Abstract: In this presentation, we will review the pharmacokinetics of commonly used anticoagulants in addition to the effects of therapeutic apheresis on a patient's coagulation status. Using this information, we will review strategies for managing patients on systemic anticoagulation who are also undergoing treatment with therapeutic apheresis.
Objectives – the learner will be able to:
- Review the pharmacokinetics and mechanism of action of commonly used anticoagulants.
- Examine the effects of therapeutic apheresis on patient's coagulation status.
- Determine the appropriate management for patients on systemic anticoagulation who require therapeutic apheresis.
|
| 9:50 - 10:05 a.m. |
Break |
| 10:05 - 10:35 a.m. |
Alloantibody Exchange
Ronald “George” Hauser, MD
Associate Professor
Yale University School of Medicine
Speaker Bio: Dr. Hauser is an Associate Professor at Yale University School of Medicine. He is the Yale-VA site director of the ACGME Informatics fellowship. He teaches “Clinical Database Management Systems and Ontologies” in the Yale School of Public Health. He designed and developed the software used to exchange transfusion histories with his co-developer, Andrew Loza. He also completed a 150-page security review, and now has carpal tunnel syndrome, almost.
Abstract: Who would not want a complete blood transfusion recipient history made possible by a national electronic blood bank exchange? Patient history review is a requirement of AABB, CAP, and the Joint Commission. At least a dozen research papers have argued for its creation. Cost effectiveness studies have confirmed its benefit. And, a case report identified a patient who narrowly averted a likely transfusion reaction because of the availability of an electronic transfusion history. But can it happen now? New advances in cloud computing and the adoption of electronic health records have brought the idea of a national electronic blood bank exchange closer than ever before. Reviving a failed commercial product, a non-profit is now offering the service at no cost. Could this possibly work? What role will the blood bank play? Join our talk to find out more.
Objectives – the learner will be able to:
- Appreciate the adoption of an electronic blood bank exchange is NOT performed by blood bank staff, but rather health system information technology, legal, and business personnel.
- Understand the chief role of the transfusion service in the adoption of a blood bank information exchange is advocacy.
|
| 10:35 - 11:20 a.m. |
Ethical Concerns in Patient Blood Management
Mary Ann Sromoski, RN, MSN, FNP-C
Program Manager
Geisinger
Speaker Bio: Mary Ann Sromoski oversees the Patient Blood Management Program and Bloodless Medicine at Geisinger in Northeast and Central Pennsylvania. Mary Ann and her team have created a comprehensive Patient Blood Management (PBM) program that includes an anemia consultative service, a Transfusion Safety Officer, an anemia pharmacist, and a 24/7 prospective review.
Mary Ann serves as a member of the Board of Directors for the Society for Advancement of Patient Blood Management, (SABM) and is a mentor to SABM members developing their PBM programs. She also serves on the AABB PBM Standards Committee, helping to author the AABB & Joint Commission Standards for Patient Blood Management. She has also co-authored the recent updates of the AABB Guideline for Massive Transfusion and the AABB Guideline for Informed Consent.
Mary Ann co-hosts the popular podcast Let's Talk PBM focused on educating patients about topics including anemia, consent, and questions to ask your doctor. Mary Ann is also proud to be a Trustee of the National Board of Directors for the Carpatho-Rusyn Society. Abstract: There are many ethical concerns surrounding blood and blood products. This presentation aims to help you understand these concerns and how you can play a role in patient-centered care.
Objectives – the learner will be able to:
- Break down the ethical concerns surrounding blood.
- Identify how laboratorians can play a role in ethical issues.
- Act out an informed consent scenario.
|
| 11:20 - 11:30 a.m. |
Closing Remarks |
Back to top
|
